HSTO Key Statistics, Chart & Performance
The current stock price of HSTO is 0.658 USD. In the past month the price decreased by -1.2%. In the past year, price decreased by -55.54%.
HSTO Technical Analysis
HSTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HSTO. While HSTO seems to be doing ok healthwise, there are quite some concerns on its profitability.
HSTO Financial Highlights
Over the last trailing twelve months HSTO reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS increased by 41.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.51% | ||
| ROE | -130.43% | ||
| Debt/Equity | 0 |
HSTO Forecast & Estimates
7 analysts have analysed HSTO and the average price target is 2.04 USD. This implies a price increase of 210.03% is expected in the next year compared to the current price of 0.658.
For the next year, analysts expect an EPS growth of 26.45% and a revenue growth -99.88% for HSTO
HSTO Ownership
HSTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B |
Related stock screener links
About HSTO
Company Profile
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. The company develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Company Info
HISTOGEN INC
10655 Sorrento Valley Road, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Richard W. Pascoe
Employees: 7
Phone: 18585263100.0
HISTOGEN INC / HSTO FAQ
What does HISTOGEN INC do?
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. The company develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
What is the stock price of HISTOGEN INC today?
The current stock price of HSTO is 0.658 USD. The price increased by 29.27% in the last trading session.
What is the dividend status of HISTOGEN INC?
HSTO does not pay a dividend.
How is the ChartMill rating for HISTOGEN INC?
HSTO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about HISTOGEN INC (HSTO) stock?
7 analysts have analysed HSTO and the average price target is 2.04 USD. This implies a price increase of 210.03% is expected in the next year compared to the current price of 0.658.
What is the GICS sector and industry of HSTO stock?
HISTOGEN INC (HSTO) operates in the Health Care sector and the Biotechnology industry.
When does HISTOGEN INC (HSTO) report earnings?
HISTOGEN INC (HSTO) will report earnings on 2023-11-08, after the market close.